Welcome to our dedicated page for Atyr Pharma SEC filings (Ticker: ATYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The aTyr Pharma, Inc. (Nasdaq: ATYR) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical stage biotechnology company focused on tRNA synthetase biology and therapies for fibrosis and inflammation, aTyr uses its filings to report on financial performance, clinical milestones and other material events related to its programs.
Investors can use this page to access current and historical reports such as Form 8-K filings, which aTyr has used to announce items like topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis and quarterly financial results. These documents provide detail on study outcomes, including primary and secondary endpoints, safety observations and the company’s stated plans to engage with the U.S. Food and Drug Administration regarding the path forward for efzofitimod.
In addition to event-driven reports, this page is the gateway to aTyr’s periodic filings on Forms 10-K and 10-Q, where the company discusses its tRNA synthetase discovery platform, clinical pipeline, risk factors and financial statements. For a biotechnology issuer, these filings are central to understanding research and development spending, cash resources, and the status of key programs in interstitial lung disease and pulmonary fibrosis.
Stock Titan enhances access to these materials with AI-powered summaries that highlight important points from lengthy filings, helping readers quickly identify items such as trial results, changes in cash runway, or updates to development plans. Users can also review insider transaction filings on Form 4, as they become available through EDGAR, to monitor equity activity by directors and officers. Together, these resources offer a structured view of aTyr Pharma’s regulatory record and the disclosures that shape the ATYR investment narrative.
aTYR Pharma (ATYR) director Paul Schimmel reported purchases totaling 1,000,000 common shares across
Federated Hermes, Inc. and related reporting persons disclose beneficial ownership of 10,544,437 shares of aTyr Pharma, Inc. common stock, representing 10.76% of the class. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control. Ownership is reported across Federated Hermes, a Voting Shares Irrevocable Trust, and three individual reporting persons who each disclose shared voting and dispositive power over the same aggregate stake. The filing includes exhibits for reporting-person classification, a joint-filing agreement, and a power of attorney.
aTYR Pharma reported results from a 268-patient global Phase 3 study in pulmonary sarcoidosis comparing efzofitimod 3.0 mg/kg and 5.0 mg/kg versus placebo over 48 weeks with a protocol-guided steroid taper. The primary steroid-reduction endpoint showed mean daily oral corticosteroid (OCS) doses of 2.79 mg for 5.0 mg/kg efzofitimod versus 3.52 mg for placebo (p=0.3313), which was not statistically significant. Secondary measures showed a statistically significant improvement in KSQ-Lung score for 5.0 mg/kg (change 10.36 vs 6.19; p=0.0479) and a higher rate of complete steroid withdrawal with KSQ-Lung improvement (29.5% vs 14.4%; p=0.0199). Change in FVC was similar between groups (−1.81 vs −2.11; p=0.7875). Treatment was generally well tolerated at both doses.